| abstract |
Enhanced plasminogen activator yields are obtained by culturing plasminogen activator producing mammalian tissue cells in an aqueous nutrient culture medium until cells have attained development to confluency or maximum population density; continuing incubation in the presence of an antimitotic agent, e.g., podophylotoxin, colchicine and derivatives thereof, vincristine, vinblastine and derivatives thereof; recovering the activator from the separated aqueous culture medium by adsorption on hydroxyapatite and elution therefrom; and purifying the activator via salt precipitation followed by DEAE cellulose chromatography and gel filtration chromatography. Plasminogen activator is provided in clinically useful amounts for treatment of thromboembolic conditions. |